Despite the fact that MGMT methylation, inducing a lack of MGMT protein expression, is found in 40% of CRC patients, TMZ and its analog dacarbazine provided limited clinical activity with an ORR under ten percent in MGMT-methylated mCRC [110]. This evidence concerns the gene MGMT and colorectal carcinoma.